IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
NCT06112314 · PRISM-MEL-301 Phase 3Recruiting
- Lead sponsor
- Immunocore Ltd (Industry)
- Enrollment
- 680 (estimated)
- Start date
- 5 Jun 2024
- Primary completion
- 16 Oct 2027 (estimated)
- Study completion
- 16 Oct 2027
- Last update posted
- 25 Feb 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- None
- Arms
- 3
Interventions
- Brenetafusp Drug
- Nivolumab Drug
- Nivolumab + Relatlimab Drug
Conditions and primary outcome
- Advanced Melanoma
Primary outcome
Progression-Free Survival (PFS) (Up to ~45 months)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06112314.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06112314 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.